Correspondence 0001193125-24-070219 from Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: March 18, 2024 · CIK: 0001501756 · Accession: 0001193125-24-070219
AI Filing Summary & Sentiment
File numbers found in text: 333-277634
Letter
ADVERUM BIOTECHNOLOGIES, INC.
100 Cardinal Way
Redwood City, California 94063
March 18, 2024
VIA EDGAR
Securities and Exchange Commission
Office of Finance
Division of Corporation Finance
100 F. Street N.E.
Washington, D.C. 20549-3010
RE: Adverum Biotechnologies, Inc.
Registration Statement on Form S-3 (File No. 333-277634)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Adverum Biotechnologies, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277634) (the “Registration Statement”) to become effective on Wednesday, March 20, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth Guernsey and Julia Boesch of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Julia Boesch of Cooley LLP, counsel to the Registrant, at (415) 693-2326, or in her absence, Kenneth Guernsey at (415) 693-2091.
[Remainder of page intentionally left blank]
Very truly yours,
ADVERUM BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ADVERUM BIOTECHNOLOGIES, INC. 100 Cardinal Way Redwood City, California 94063 March 18, 2024 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 RE: Adverum Biotechnologies, Inc. Registration Statement on Form S-3 (File No. 333-277634) Request for Acceleration of Effective Date Ladies and Gentlemen: Adverum Biotechnologies, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-277634) (the “Registration Statement”) to become effective on Wednesday, March 20, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth Guernsey and Julia Boesch of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Julia Boesch of Cooley LLP, counsel to the Registrant, at (415) 693-2326, or in her absence, Kenneth Guernsey at (415) 693-2091. [Remainder of page intentionally left blank] Very truly yours, ADVERUM BIOTECHNOLOGIES, INC. By: /s/ Linda Rubinstein Name: Linda Rubinstein Title: Chief Financial Officer cc: Kenneth Guernsey, Cooley LLP Julia Boesch, Cooley LLP